Intellia Therapeutics, Inc. (NTLA)
14.92
+0.14
(+0.98%)
USD |
NASDAQ |
Apr 15, 16:00
14.92
0.00 (0.00%)
After-Hours: 20:00
Intellia Therapeutics Research and Development Expense (Annual) : 379.09M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Recursion Pharmaceuticals, Inc. | 425.27M |
| Personalis, Inc. | 50.26M |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Novavax, Inc. | 336.82M |
| KalVista Pharmaceuticals, Inc. | 55.64M |